PHILADELPHIA, Jan. 19, 2011 /PRNewswire/ — Wolters Kluwer
Health today announced a joint venture with leading China drug
information provider Medicom to deliver clinical decision support
to doctors in China as the country prepares for significant changes
to its healthcare system. The deal allows Wolters Kluwer Health to
expand its market-leading Clinical Decision Support (CDS) and drug
information business into the rapidly growing China market and
creates a needed drug information infrastructure in China.
“The clinical decision support market in China is at a critical
juncture, similar to what we saw in the U.S. market many years
ago,” said Arvind Subramanian, President & CEO, Wolters Kluwer
Health Clinical Solutions. “Our agreement with Medicom gives
Wolters Kluwer Health a strong entry point in China and creates a
solid foundation for us to introduce more advanced CDS products and
solutions that will give healthcare professionals in China
unparalleled access to evidence-based medicine for the advancement
of healthcare.”
Medicom, located in the city of Chengdu in the Sichuan Province,
has a strong footprint in the China healthcare market, providing
drug information and services. Its products and services are highly
complementary to those of Wolters Kluwer Health’s Clinical
Solutions business, which offers healthcare professionals fast
access to evidence-based medical information that helps clinicians
effectively manage patient care on a daily basis. The combined
offering creates a robust library of clinical content not
previously available in China that physicians can access at the
point of learning as well as at the point of care with
patients.
The announcement comes as the Chinese government is focused on
healthcare reform to conform standards of care and an increasing
number of doctors in China prepare to pursue graduate school
degrees.
“Our joint venture with Wolters Kluwer Health is a strategic fit
for Medicom as we
‘/>”/>
